Study S001347

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03929744
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 133
Start: 2019-06-12
Primary completion: 2020-11-02
Lead sponsor: Eli Lilly and Company
Conditions: Healthy
Interventions: DRUG:LY3502970; DRUG:Placebo; DRUG:Atorvastatin; DRUG:Simvastatin; DRUG:Midazolam
Results posted: TRUE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J2A-MC-GZGA

Registered primary outcomes

Parts A and B: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug [Baseline through Follow-up (up to Day 42)]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004741	Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Ma X, Diabetes therapy : research, treatment and education of diabetes and related disorders	2024	Randomized trial	PMID 38402332 DOI	cites ClinicalTrials.gov:NCT03929744; registry reference DERIVED:38402332
R0055527	336-OR: A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects EDWARD J. PRATT, Diabetes	2022	Randomized trial	DOI	cites ClinicalTrials.gov:NCT03929744